A new study report reveals that Nivolumab –a successful Anti PD-1 drug can now help in improving the overall 5-year survival of the patients having advanced cancers. A new study conducted by a team of researchers at the leading John Hopkins Kimmel Cancer Center, Baltimore, has revealed that the famous cancer drug namely Nivolumab has been successful in improving the overall cancer survival rate of the cancer patients having advanced forms of cancer. The results of the study have shown significant improvements in the 5-year survival rate of the patients dealing with several forms of advanced cancers. The patients were given the dosage of anti PD-1 Nivolumab multiple times to observe the results.
The Revolutionary Study Emphasizing the Importance of Nivolumab
The results of the study got published in the journal named “JAMA Oncology.” The study involved as many as 270 patients having cases of advanced melanoma along with NSCLC (Non-small-cell Lung cancer), and renal cell carcinoma. The patients were given treatment at 13 various cancer treatment centers across the United States, and those who had exhausted other forms of cancer treatments before trying out the dosage of Nivolumab.
The Results of the Study
The overall results of the study have been quite promising as far as improving the survival rate of patients with advanced cancer is concerned. Before the introduction of the drug dosage, the patients with advanced melanoma had only 5 percent of surviving three years upon conventional cancer treatments. Similarly, the patients having NSCLC had just 6 percent of the chances of surviving post five years. As per the results of the all-new study, it is revealed that for patients having advanced melanoma, the survival rate has improved to reach as much as 34.2 percent of the 5-year survival rate and around 15.6 percent of the 5-year survival rate for patients with NSCLC.
Suzanne Topalian –MD & Professor of Surgery at the Bloomberg Kimmel Institute for Cancer, states that the all-new study has been effective in providing the much-needed information on the long-term clinical results that are associated with Nivolumab. Nivolumab is a drug that is responsible for blocking the activity of a specific molecule named PD-1. The drug also helps in removing restraints on the T-cells that can kill cancer.
In addition to the overall improved survival rate of the patients with this study, the researchers were also able to obtain additional information about the results of the study.